Head-to-head · free

Teva Pharmaceutical Industries Limited vs First Tracks Biotherapeutics Inc

TEVA vs TRAX — return on capital, cash generation, margins and balance sheet side by side.

TEVA

1 / 2

measures where TEVA leads

TRAX

1 / 2

measures where TRAX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureTEVA · FY2025TRAX
Revenue$1.5B—
Net income$1.4B—
Revenue growth (yearly, multi-year)-44.6%—
Free cash flow——
Free cash flow margin——
Net cash / (debt)——
ROIC——
Return on equity21.2%-40.9%
Gross margin51.8%—
Operating margin22.9%—
Net debt / EBITDA4.19x0.69x

Figures are as reported by each company; latest fiscal year shown.

Where Teva Pharmaceutical Industries Limited's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TEVA profile →

Where First Tracks Biotherapeutics Inc's cash went

Not reported yet.

Full TRAX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons